NFKB1 and diffuse large B-cell lymphoma: Futher studies are required to reliably identify dogs with ABC-DLBCL that are likely to respond to NF-κB inhibition and to determine whether repeat doses of NBD peptide, administered in combination with systemic chemotherapy to dogs with relapsed, refractory ABC-like DLBCL will have substantial therapeutic benefit.